(2023). Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. Eclinicalmedicine, 58, 101932. http://doi.org/10.1016/j.eclinm.2023.101932
. observational research
(2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133-141. http://doi.org/10.1080/15412555.2022.2045265
. (2022). Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd, 19, 109-117. http://doi.org/10.1080/15412555.2022.2035705
.